Compare · ATXI vs KDNY
ATXI vs KDNY
Side-by-side comparison of Avenue Therapeutics Inc. (ATXI) and Chinook Therapeutics Inc. (KDNY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ATXI and KDNY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- KDNY is the larger of the two at $670.6M, about 45.2x ATXI ($14.8M).
- KDNY has more recent analyst coverage (5 ratings vs 0 for ATXI).
- Company
- Avenue Therapeutics Inc.
- Chinook Therapeutics Inc.
- Price
- $0.42-50.37%
- $40.33+0.04%
- Market cap
- $14.8M
- $670.6M
- 1M return
- +0.00%
- -
- 1Y return
- +0.00%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2015
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 5
Avenue Therapeutics Inc.
Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was incorporated in 2015 and is based in New York, New York.
Chinook Therapeutics Inc.
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase Ib trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. The company is headquartered in Seattle, Washington.
Latest ATXI
- SEC Form 10-Q filed by Avenue Therapeutics Inc.
- SEC Form 10-K filed by Avenue Therapeutics Inc.
- Avenue Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease
- Amendment: SEC Form SCHEDULE 13D/A filed by Avenue Therapeutics Inc.
- Large owner Fortress Biotech, Inc. was granted 111,209 shares, increasing direct ownership by 34% to 439,733 units (SEC Form 4)
- Avenue Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form EFFECT filed by Avenue Therapeutics Inc.
- SEC Form POS AM filed by Avenue Therapeutics Inc.
- SEC Form RW filed by Avenue Therapeutics Inc.
Latest KDNY
- SEC Form SC 13D/A filed by Chinook Therapeutics Inc. (Amendment)
- SEC Form 15-12G filed by Chinook Therapeutics Inc.
- SEC Form EFFECT filed by Chinook Therapeutics Inc.
- SEC Form SC 13D filed by Chinook Therapeutics Inc.
- SEC Form S-8 POS filed by Chinook Therapeutics Inc.
- SEC Form S-8 POS filed by Chinook Therapeutics Inc.
- SEC Form S-8 POS filed by Chinook Therapeutics Inc.
- SEC Form S-8 POS filed by Chinook Therapeutics Inc.
- SEC Form S-8 POS filed by Chinook Therapeutics Inc.
- SEC Form S-8 POS filed by Chinook Therapeutics Inc.